Han Li
Impact in
- Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Co-authors
- Chengyuan Liang (1 shared paper)Wenqiang Cao (1 shared paper)Lei Tian (1 shared paper)Ke Su (9 shared papers)Jiayun Zhang (1 shared paper)Hong Liu (1 shared paper)Jingyi Li (1 shared paper)Xiaodong Ren (1 shared paper)
- Journals
- Frontiers in Oncology (4 papers)Annals of Oncology (4 papers)International Journal of Molecular Sciences (3 papers)World Journal of Gastroenterology (3 papers)Clinical Neurology and Neurosurgery (2 papers)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Han Li
87 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 119
- Hepatology 82
- Cancer Research 129
- Immunology 128
- Infectious Diseases 109
- Oncology 147
Countries citing papers authored by Han Li
This map shows the geographic impact of Han Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Han Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Han Li more than expected).
Fields of papers citing papers by Han Li
This network shows the impact of papers produced by Han Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Han Li. The network helps show where Han Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Han Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 96 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 159 | |
| 2 | 2021 | 75 | |
| 3 | 2022 | 73 | |
| 4 | 2015 | 69 | |
| 5 | 2015 | 46 | |
| 6 | 2023 | 42 | |
| 7 | 2022 | 38 | |
| 8 | 2021 | 37 | |
| 9 | 2023 | 33 | |
| 10 | 2022 | 33 | |
| 11 | 2023 | 33 | |
| 12 | 2022 | 32 | |
| 13 | 2019 | 29 | |
| 14 | 2021 | 23 | |
| 15 | 2016 | 22 | |
| 16 | 2023 | 21 | |
| 17 | 2017 | 19 | |
| 18 | 2022 | 17 | |
| 19 | 2020 | 17 | |
| 20 | 2021 | 17 |
About Han Li
Han Li is a scholar working on Oncology, Surgery, Molecular Biology, Hepatology and Immunology, having authored 96 papers that have together received 1.2k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (10 papers), Cancer Cells and Metastasis (6 papers), Cancer Immunotherapy and Biomarkers (6 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers), Lung Cancer Research Studies (5 papers), Osteoarthritis Treatment and Mechanisms (3 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Immune cells in cancer (3 papers). The work is most often cited by research in Hepatology (82 citations), Cancer Research (129 citations), Immunology (128 citations), Infectious Diseases (109 citations) and Oncology (147 citations). Han Li has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Chengyuan Liang, Wenqiang Cao, Lei Tian, Ke Su, Jiayun Zhang, Hong Liu, Jingyi Li, Xiaodong Ren, Minyi Jia and Betty Yuen Kwan Law. Their work appears in journals such as Frontiers in Oncology, Annals of Oncology, International Journal of Molecular Sciences, World Journal of Gastroenterology and Clinical Neurology and Neurosurgery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.